ClinicalInvolving direct observation of a patient. Education & Guidelines

Knowledge transfer and clinical impact

Through the Aurelia Initiative, Myeloma Canada ensures that advances in research are quickly adopted into improvements at the bedside of care. By supporting the knowledge transfer from research to clinical practice, Aurelia brings together researchers, clinicians, and patients to work together to develop and accelerate the adoption of evidence-based Canadian guidelines to shape the best clinical practices for Canadian patients. This helps ensure new discoveries are quickly shared, adopted, and results in better outcomes for people living with myeloma.

People of different races hold hands in a unity circle of support

Myeloma consensus guidelines

To improve consistency in myeloma diagnosis, treatment, and management nationwide, Myeloma Canada led the development of Canada’s first evidence-based consensus guidelines in collaboration with leading experts. These peer-reviewed publications provide national recommendations that reflect both best practices and provincial differences in access and funding. Designed to be practical and relevant, the guidelines support clinicians with clear diagnostic and treatment guidance, helping ensure high-quality, standardized care for people living with myeloma, no matter where you live in Canada.

View published consensus guidelines

Continuing Medical Education (CME) for primary care providers

Myeloma Canada has partnered with Queen’s University to develop an on-demand, accredited CME learning program for primary care providers. This program enhances knowledge of myeloma diagnosis, referral pathways, and ongoing management, helping patients access specialized care sooner and receive more coordinated, effective treatment throughout their journey.

Learn more about our CME program

Supporting the Quebec Plasma Cell Dyscrasia Group

The Quebec Plasma Cell Dyscrasia Group (also known as GMPQ) is a nonprofit organization that brings together physicians who specialize in plasma cell diseases in the province. Its mission is to promote excellence in myeloma care by encouraging the dissemination of knowledge and clinical research.

Myeloma Canada has provided support to the GMPQ since its inception in 2021, first with in-kind assistance with the development of their first two guidelines for the treatment of myeloma. As of 2024, Myeloma Canada has provided them with financial assistance to support their educational activities that ultimately ensure that myeloma patients in Quebec benefit from the most up-to-date, evidence-based care.

Learn about the GMPQ